522 - Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

PF

Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine/Attending Gastroenterologist
Yale University School of Medicine/PACT-Gastroenterology Center
Westport, Connecticut, United States
Erik R. Dubberke, MD, MSPH

Professor
Washington University
Saint Louis, Missouri, United States
AG

Amy Guo, PhD

Senior Director, Health Outcome Research
Ferring Pharmaceuticals
parsippany, New Jersey, United States
AH

Adam Harvey, PhD

Clinical Scientist
Ferring Pharmaceuticals
Roseville, Minnesota, United States
MY

Min Yang, MD, PhD

Analysis Group, Inc.
Boston, Massachusetts, United States
VG

Viviana García-Horton, PhD

Analysis Group
New York City, New York, United States
MF

Mirko Fillbrunn, PhD

Analysis Group, Inc.
Boston, Massachusetts, United States
Glenn S. Tillotson, PhD

CONSULTANT MICROBIOLOGIST
GST Micro LLC
NORTH, Virginia, United States
Lindy Bancke, PharmD

Head of Clinical Development
Rebiotix, a Ferring Company
Roseville, Minnesota, United States

Kevin W. Garey, PharmD, MS (he/him/his)

Professor and Chair
University of Houston
Houston, TX, United States